Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2020 1
2021 2
2022 2
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Hokuriku-plus familial hypercholesterolaemia registry study: rationale and study design.
Tada H, Okada H, Yoshida S, Shimojima M, Nomura A, Tsuda T, Mori M, Takashima SI, Kato T, Usui S, Sakata K, Hayashi K, Fujino N, Inazu A, Takahara S, Imai Y, Matsubara T, Nohara A, Miwa K, Namura M, Terai H, Yoshida T, Araki T, Minamoto M, Aburao T, Ito Y, Nakanishi C, Kawasaki S, Todo Y, Koizumi J, Kita Y, Matsumoto H, Shintaku H, Hodatsu A, Ino H, Higashikata T, Takata M, Misawa K, Yamaguchi M, Noji Y, Osato K, Mabuchi T, Ichise T, Kaku B, Katsuda S, Fujimoto M, Uchiyama K, Fujioka K, Nakahashi T, Nozue T, Michishita I, Usuda K, Otowa K, Okeie K, Hirota S, Aburadani I, Kurokawa K, Takatori O, Hondo S, Oda H, Takata S, Murai H, Kinoshita M, Nagai H, Sekiguchi Y, Sakagami S, Omi W, Fujita C, Katsuki T, Ootsuji H, Igarashi A, Nakano M, Okura S, Maeno K, Mitamura Y, Sugimoto N, Yamamoto M, Akao H, Kajinami K, Takamura M, Kawashiri MA. Tada H, et al. Among authors: takahara s. BMJ Open. 2020 Sep 10;10(9):e038623. doi: 10.1136/bmjopen-2020-038623. BMJ Open. 2020. PMID: 32912992 Free PMC article.
Serum Laminin γ2 Monomer as a Diagnostic and Predictive Biomarker for Hepatocellular Carcinoma.
Yamashita T, Koshikawa N, Shimakami T, Terashima T, Nakagawa M, Nio K, Horii R, Iida N, Kawaguchi K, Arai K, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kitao A, Kobayashi S, Takahara S, Imai Y, Yoshimura K, Murayama T, Nakamoto Y, Yoshida E, Yoshimura T, Seiki M, Kaneko S. Yamashita T, et al. Among authors: takahara s. Hepatology. 2021 Aug;74(2):760-775. doi: 10.1002/hep.31758. Epub 2021 Apr 28. Hepatology. 2021. PMID: 33609304
Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial.
Izumi K, Shima T, Mita K, Kato Y, Kamiyama M, Inoue S, Tanaka N, Hoshi S, Okamura T, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Kadono Y, Mizokami A. Izumi K, et al. Among authors: takahara s. Eur Urol Open Sci. 2022 May 19;41:16-23. doi: 10.1016/j.euros.2022.04.016. eCollection 2022 Jul. Eur Urol Open Sci. 2022. PMID: 35813251 Free PMC article.
Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET).
Takeuchi S, Yanagitani N, Seto T, Hattori Y, Ohashi K, Morise M, Matsumoto S, Yoh K, Goto K, Nishio M, Takahara S, Kawakami T, Imai Y, Yoshimura K, Tanimoto A, Nishiyama A, Murayama T, Yano S. Takeuchi S, et al. Among authors: takahara s. Transl Lung Cancer Res. 2021 Jan;10(1):314-325. doi: 10.21037/tlcr-20-549. Transl Lung Cancer Res. 2021. PMID: 33569315 Free PMC article.
Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol.
Takeuchi S, Murayama T, Yoshimura K, Kawakami T, Takahara S, Imai Y, Kuribayashi Y, Nagase K, Goto K, Nishio M, Hasegawa Y, Satouchi M, Kiura K, Seto T, Yano S. Takeuchi S, et al. Among authors: takahara s. J Med Invest. 2017;64(3.4):317-320. doi: 10.2152/jmi.64.317. J Med Invest. 2017. PMID: 28955006 Free article. Clinical Trial.
Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study.
Kadono Y, Konaka H, Nohara T, Izumi K, Anai S, Fujimoto K, Koguchi T, Ishibashi K, Kawai N, Nakane K, Iba A, Masumori N, Takahara S, Mizokami A. Kadono Y, et al. Among authors: takahara s. Cancers (Basel). 2023 May 13;15(10):2745. doi: 10.3390/cancers15102745. Cancers (Basel). 2023. PMID: 37345082 Free PMC article.
Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa.
Mita K, Izumi K, Goriki A, Tasaka R, Hatayama T, Shima T, Kato Y, Kamiyama M, Inoue S, Tanaka N, Hoshi S, Okamura T, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Kadono Y, Mizokami A. Mita K, et al. Among authors: takahara s. Cancers (Basel). 2024 Jan 24;16(3):508. doi: 10.3390/cancers16030508. Cancers (Basel). 2024. PMID: 38339260 Free PMC article.
Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial.
Izumi K, Mizokami A, Namiki M, Inoue S, Tanaka N, Yoshio Y, Ishibashi K, Kamiyama M, Kawai N, Enokida H, Shima T, Takahara S. Izumi K, et al. Among authors: takahara s. BMC Cancer. 2017 Oct 10;17(1):677. doi: 10.1186/s12885-017-3661-2. BMC Cancer. 2017. PMID: 29017493 Free PMC article. Clinical Trial.